KORU Medical Systems (NASDAQ:KRMD – Get Free Report) and Biomerica (NASDAQ:BMRA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.
Insider and Institutional Ownership
58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 18.5% of KORU Medical Systems shares are owned by company insiders. Comparatively, 12.3% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for KORU Medical Systems and Biomerica, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KORU Medical Systems | 1 | 1 | 4 | 0 | 2.50 |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
KORU Medical Systems presently has a consensus price target of $7.00, suggesting a potential upside of 126.54%. Biomerica has a consensus price target of $9.00, suggesting a potential upside of 466.04%. Given Biomerica’s higher probable upside, analysts plainly believe Biomerica is more favorable than KORU Medical Systems.
Profitability
This table compares KORU Medical Systems and Biomerica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KORU Medical Systems | -4.03% | -10.63% | -6.51% |
| Biomerica | -115.50% | -142.81% | -77.83% |
Valuation & Earnings
This table compares KORU Medical Systems and Biomerica”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KORU Medical Systems | $41.13 million | 3.45 | -$2.64 million | ($0.04) | -77.25 |
| Biomerica | $4.34 million | 1.13 | -$3.78 million | ($1.64) | -0.97 |
KORU Medical Systems has higher revenue and earnings than Biomerica. KORU Medical Systems is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
KORU Medical Systems has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.
Summary
KORU Medical Systems beats Biomerica on 12 of the 14 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
